ID: MRFR/Pharma/2192-HCR | 75 Pages | Author: Kinjoll Dey | March 2024
1 Introduction
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s five forces model
4.1.1 Bargaining Power of suppliers
4.1.2 Bargaining Power of Customer
4.1.3 Intensity of Competitor’s
4.1.4 Threat of New Entrants
5 Global Nucleic Acid-based Therapeutics Market, by Technology
5.1 Introduction
5.1.1 Anti-Sense and Anti-Gene
5.1.2 Short Inhibitory Sequences
5.1.3 Gene Transfer Therapy
5.1.4 Nucleoside Analogs
5.1.5 Ribozymes
5.1.6 Aptamers
5.1.7 Others
6 Global Nucleic Acid-based Therapeutics Market, by Applications
6.1 Introduction
6.1.1 Monogenetic disorders
6.1.2 Multi-genetic disorders
7 Global Nucleic Acid-based Therapeutics Market, by End User
7.1 Introduction
7.1.1 Hospitals
7.1.3 Academic & Research Institutes
7.1.6 Others
8 Global Nucleic Acid-based Therapeutics Market, by Regions
8.1 Introduction
8.1.1 Americas
8.1.1.1 North America
8.1.1.2 South America
8.1.2 Europe
8.1.2.1 Germany
8.1.2.2 France
8.1.2.3 UK
8.1.2.4 Italy
8.1.2.5 Spain
8.1.2.6 Rest of Europe
8.1.3 Asia Pacific
8.1.3.1 Japan
8.1.3.2 China
8.1.3.3 India
8.1.3.4 Republic of Korea
8.1.3.5 Rest of Asia Pacific
8.1.4 Middle East & Africa
9 Company Landscape
9.1 Introduction
9.1.1 Mergers Acquisitions
9.1.2 Collaborations
9.1.3 Release/New Product Launches
9.1.4 Other (Expansion, Updates, Partnership)
10 Company Profile
10.1 Wave Life Sciences Ltd., Copernicus Therapeutics Inc.
10.1.1 Company Overview
10.1.2 Product/Business Segment Overview
10.1.3 Financials
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Imugene
10.2.1 Overview
10.2.2 Product/Business Segment Overview
10.2.3 Financials
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Caperna
10.3.1 Overview
10.3.2 Product/Business Segment Overview
10.3.3 Financials
10.3.4 Key Developments
10.3.5 SWOT Analysis
10.4 Phylogica
10.4.1 Overview
10.4.2 Product/Business Segment Overview
10.4.3 Financials
10.4.4 Key Developments
10.4.5 SWOT Analysis
10.5 Protagonist Therapeutics
10.5.1 Overview
10.5.2 Product/Business Segment Overview
10.5.3 Financials
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Benitec Biopharma
10.6.1 Overview
10.6.2 Product/Business Segment Overview
10.6.3 Financials
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 EGEN (Expression Genetics)
10.7.1 Overview
10.7.2 Product/Business Segment Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 BioMedica (Oxford BioMedica)
10.8.1 Overview
10.8.2 Product/Business Segment Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.9 Transgene
10.9.1 Overview
10.9.2 Product/Business Segment Overview
10.9.3 Financials
10.9.4 Key Developments
10.9.5 SWOT Analysis
10.10 Others
11 Appendix
List of Tables
TABLE 1 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, 2023-2030 (USD MILLION)
TABLE 2 GLOBAL NUCLEIC ACID- BASED THERAPEUTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 3 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY APPLICATIONS, 2023-2030 (USD MILLION)
TABLE 4 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 5 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY REGION, 2023-2030 (USD MILLION)
List of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY TECHNOLOGY
FIGURE 4 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY APPLICATIONS
FIGURE 5 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY END USER
FIGURE 6 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY REGION
FIGURE 7 GLOBAL NUCLEIC ACID - BASED THERAPEUTICS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
Nucleic Acid-based Therapeutics Market Segmentation
Nucleic Acid-based Therapeutics Technology Outlook (USD Billion, 2019-2030)
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Nucleic Acid-based Therapeutics Application Outlook (USD Billion, 2019-2030)
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
cardiovascular Diseases etc.
Nucleic Acid-based Therapeutics End Users Outlook (USD Billion, 2019-2030)
Hospitals
Academic & Research Institutes
Nucleic Acid-based Therapeutics Regional Outlook (USD Billion, 2019-2030)
North America Outlook (USD Billion, 2019-2030)
North America Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
North America Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
cardiovascular Diseases etc.
North America Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
US Outlook (USD Billion, 2019-2030)
US Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
US Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
cardiovascular Diseases etc
US Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
CANADA Outlook (USD Billion, 2019-2030)
CANADA Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
CANADA Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
cardiovascular Diseases etc.
CANADA Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
Europe Outlook (USD Billion, 2019-2030)
Europe Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Europe Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
cardiovascular Diseases etc.
Europe Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
Germany Outlook (USD Billion, 2019-2030)
Germany Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Germany Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
cardiovascular Diseases etc.
Germany Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
France Outlook (USD Billion, 2019-2030)
France Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
France Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
Cardiovascular Diseases etc.
France Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
UK Outlook (USD Billion, 2019-2030)
UK Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
UK Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
cardiovascular Diseases etc.
UK Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
ITALY Outlook (USD Billion, 2019-2030)
ITALY Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
ITALY Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
cardiovascular Diseases etc.
ITALY Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
SPAIN Outlook (USD Billion, 2019-2030)
Spain Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Spain Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
Cardiovascular Diseases etc.
Spain Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
Rest of Europe Outlook (USD Billion, 2019-2030)
Rest of Europe Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
REST OF EUROPE Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
Cardiovascular Diseases etc.
REST OF EUROPE Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
Asia-Pacific Outlook (USD Billion, 2019-2030)
Asia-Pacific Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Asia-Pacific Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
Cardiovascular Diseases etc.
Asia-Pacific Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
China Outlook (USD Billion, 2019-2030)
China Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
China Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
Cardiovascular Diseases etc.
China Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
Japan Outlook (USD Billion, 2019-2030)
Japan Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Japan Nucleic Acid-based Therapeutics by Technology
Metal
Polymer
Others
Japan Nucleic Acid-based Therapeutics by Applications
Minimally Invasive Spine Surgery
Open Spine Surgery
Japan Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
India Outlook (USD Billion, 2019-2030)
India Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
India Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
Cardiovascular Diseases etc.
India Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
Australia Outlook (USD Billion, 2019-2030)
Australia Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Australia Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
Cardiovascular Diseases etc.
Australia Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)
Rest of Asia-Pacific Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Rest of Asia-Pacific Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
Cardiovascular Diseases etc.
Rest of Asia-Pacific Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
Rest of the World Outlook (USD Billion, 2019-2030)
Rest of the World Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Rest of the World Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
Cardiovascular Diseases etc.
Rest of the World Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
Middle East Outlook (USD Billion, 2019-2030)
Middle East Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Middle East Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
Cardiovascular Diseases etc.
Middle East Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
Africa Outlook (USD Billion, 2019-2030)
Africa Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Africa Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
Cardiovascular Diseases etc.
Africa Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes
Latin America Outlook (USD Billion, 2019-2030)
Latin America Nucleic Acid-based Therapeutics by Technology
Anti-Sense and Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Latin America Nucleic Acid-based Therapeutics by Applications
Monogenetic disorders
Thalassemia
Sickle cell anemia
Hemophilia
Cystic Fibrosis etc.
Multi-genetic disorders
Cancer
Diabetes
Neurodegenerative Diseases
Cardiovascular Diseases etc.
Latin America Nucleic Acid-based Therapeutics by End Users
Hospitals
Academic & Research Institutes